In the News

2021

March 4, 2021
CRISPR 2.0: Base Editing in the Groove
Genetic Engineering & Biotechnology News
January 19, 2021
Beam, Verve stockpile cash as investors bank on gene editing progress
BioPharma Dive
January 12, 2021
Why Verve chose base editing over standard CRISPR for its lead CV candidate
BioCentury
January 12, 2021
With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
STAT News
January 12, 2021
Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable
Endpoints News
January 12, 2021
The biotech Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.
Business Insider

2020

October 1, 2020
BBJ honors 2020 Best Places to Work award winners
Boston Business Journal
September 30, 2020
The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them
Endpoints News
August 14, 2020
How a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times
CNBC
August 13, 2020
COVID-19 testing to keep employees safe
CNBC
June 29, 2020
Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks
Endpoints News
June 27, 2020
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
STAT News
June 27, 2020
A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys
The New York Times
June 18, 2020
Big Tech Zeros In on the Virus-Testing Market
The New York Times
June 17, 2020
Biotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal
The Wall Street Journal
June 16, 2020
For some biotech employees in the age of COVID-19, the workday starts at the bathroom sink
The Boston Globe
June 11, 2020
Verve Therapeutics to Take On Heart Disease With $63 Million Funding Round
The Wall Street Journal
June 11, 2020
Verve banks $63M to move gene-editing heart attack treatment toward clinic
FierceBiotech
June 11, 2020
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Xconomy
June 11, 2020
Verve raises another $63m to develop gene-editing treatment for heart disease
The Boston Globe

2019

June 11, 2019
10-year-old’s cholesterol was over 800. Can CRISPR fix the problem?
The Philadelphia Inquirer
May 10, 2019
One-off injection may drastically reduce heart attack risk
The Guardian
May 7, 2019
With a superstar cardiologist as its CEO, new CRISPR company targets heart disease
STAT
May 7, 2019
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
Endpoints News

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com